

# **Assessment of Serum IgA in Pediatric Patients with Recurrent Otitis Media**

*Thesis*

Submitted for partial fulfillment of Master Degree  
in Pediatrics

*By*

**Reham Abd El Latif Ahmed Gaafar**

M.B., B.Ch.

Faculty of Medicine – Ain Shams University

*Under Supervision of*

**Prof. Dr. Shereen Medhat Reda**

Professor of Pediatrics

Faculty of Medicine - Ain Shams University

**Dr. Tamer Ali Youssef**

Assistant Professor of Otolaryngology

Faculty of Medicine - Ain Shams University

**Dr. Reem Ahmed El-Feky**

Lecturer of Pediatrics

Faculty of Medicine - Ain Shams University

**Faculty of Medicine  
Ain Shams University  
2012**



وَأَنْزَلَ اللَّهُ عَلَيْكَ  
الْكِتَابَ وَالْحِكْمَةَ  
وَعَلَّمَكَ مَا لَمْ تَكُنْ  
تَعْلَمُ وَكَانَ فَضْلُ  
اللَّهِ عَلَيْكَ عَظِيمًا

صدق الله العظيم

سورة النساء الآية (١١٢)



## Acknowledgement

*First of all, all gratitude is to **Allah** almighty for blessing this work until it has been ended, as part of His generous help throughout my life.*

*I can't find the words to express my deep gratitude and love to **Prof. Shereen Reda**, Professor of Pediatrics, Ain Shams University, for her close and kind supervision, continuous help and encouragement throughout the whole work. I really enjoyed my work under her supervision, and I had a precious chance to learn from her experience. It was an honor to work under her guidance and meticulous care.*

*I am grateful to **Dr. Tamer Ali Youssef**, Assistant Professor of Otolaryngology, Ain Shams University, for his sincere help and useful advice throughout the work.*

*I am deeply indebted to **Dr. Reem EL Feki**, Lecturer of Pediatrics, Ain Shams University, for her kind help, her guidance, and her useful advice during my study.*

*I also have to thank the ENT clinic doctors and nurses, infants, children, and their parents for their cooperation and patience.*

*A great deal of my gratitude goes to my husband for his help and encouragement.*

# Contents

| <i>Subjects</i>                          | <i>Page No.</i> |
|------------------------------------------|-----------------|
| List of Abbreviations .....              | i               |
| List of Tables .....                     | iii             |
| List of Figures.....                     | iv              |
| Introduction.....                        | 1               |
| Aim of the work.....                     | 3               |
| Review of Literature                     |                 |
| - Introduction to the immune system..... | 4               |
| - Otitis media .....                     | 28              |
| Subjects and Methods.....                | 42              |
| Results .....                            | 48              |
| Discussion.....                          | 67              |
| Recommendations .....                    | 75              |
| Summary.....                             | 76              |
| References .....                         | 79              |
| Arabic Summary .....                     | —               |

---

## List of Abbreviations

---

|                  |                                             |
|------------------|---------------------------------------------|
| <b>Ags</b>       | : Antigens                                  |
| <b>Anti –tTG</b> | : Anti - tissue transglutaminase            |
| <b>AOM</b>       | : Acute otitis media                        |
| <b>CVID</b>      | : Common variable immunodeficiency          |
| <b>EAA</b>       | : Extrensic Allergic Alvéolites             |
| <b>ETD</b>       | : Eustechian tube dysfunction               |
| <b>Fc</b>        | : Fragment crystallizable                   |
| <b>GI</b>        | : Gasterointestinal                         |
| <b>HCT</b>       | : Hematocrit                                |
| <b>HGB</b>       | : Hemoglobin                                |
| <b>HIV</b>       | : Human immunodeficiency virus              |
| <b>HLA</b>       | : Human leukocytic antigen                  |
| <b>Ig</b>        | : Immunoglobulin                            |
| <b>IgA</b>       | : Immunoglobulin A                          |
| <b>IgD</b>       | : Immunoglobulin D                          |
| <b>IgE</b>       | : Immunoglobulin E                          |
| <b>IgG</b>       | : Immunoglobulin G                          |
| <b>IgM</b>       | : Immunoglobulin M                          |
| <b>IL</b>        | : Interleukins                              |
| <b>IVIG</b>      | : Intravenous immunoglobulin                |
| <b>MALT</b>      | : Mucosal-associated lymphoid tissues       |
| <b>MCHC</b>      | : Mean corpuscular hemaglobin concentration |
| <b>MCV</b>       | : Mean corpuscular volume                   |
| <b>MMR</b>       | : Measles, Mumps, Rubella vaccine           |

|              |                                                                                |
|--------------|--------------------------------------------------------------------------------|
| <b>NSAID</b> | : Non steroidal anti-inflammatory drugs                                        |
| <b>O.M</b>   | : Otitis media                                                                 |
| <b>PID</b>   | : Primary immunodeficiency                                                     |
| <b>PIgA</b>  | : Polymeric IgA                                                                |
| <b>PLT</b>   | : Platelets                                                                    |
| <b>ROM</b>   | : Recurrent otitis media                                                       |
| <b>SD</b>    | : Standard deviation                                                           |
| <b>TACI</b>  | : Transmembrane activator, calcium-modulator and cyclophilin ligand interactor |
| <b>TLC</b>   | : Total leukocytic count                                                       |
| <b>URTI</b>  | : Upper respiratory tract infection                                            |

## List of Tables

| <i>Table No.</i>  | <i>Title</i>                                                                                 | <i>Page No.</i> |
|-------------------|----------------------------------------------------------------------------------------------|-----------------|
| <b>Table (1):</b> | IgG subclasses .....                                                                         | 8               |
| <b>Table (2):</b> | Reference values for immunoglobulin in sera of normal subjects by age. ....                  | 45              |
| <b>Table (3):</b> | Demographic data of & the clinical presentations of the patients of the studied groups ..... | 59              |
| <b>Table (4):</b> | Laboratory investigations in different studied groups .....                                  | 61              |
| <b>Table (5):</b> | Demographic data & clinical presentation of group A & group B .....                          | 64              |
| <b>Table (6):</b> | Laboratory findings of group A and group B .....                                             | 66              |

## List of Figures

| <i>Figure No.</i>   | <i>Title</i>                                                                     | <i>Page No.</i> |
|---------------------|----------------------------------------------------------------------------------|-----------------|
| <b>Figure (1):</b>  | B cell development & differentiation.....                                        | 6               |
| <b>Figure (2):</b>  | Dimeric structure of IgA .....                                                   | 10              |
| <b>Figure (3):</b>  | Age variations in our cohort.....                                                | 49              |
| <b>Figure (4):</b>  | Gender variation among studied sample .....                                      | 49              |
| <b>Figure (5):</b>  | Gender variation in different age group .....                                    | 50              |
| <b>Figure (6):</b>  | Consanguinity in our cohort. ....                                                | 50              |
| <b>Figure (7):</b>  | Weight percentiles of our cohort. ....                                           | 51              |
| <b>Figure (8):</b>  | Height percentiles of our study .....                                            | 51              |
| <b>Figure (9):</b>  | Classification of otitis media.....                                              | 52              |
| <b>Figure (10):</b> | Type of ear infections in different age<br>groups .....                          | 53              |
| <b>Figure (11):</b> | Adenoid enlargement in the studied<br>sample.....                                | 53              |
| <b>Figure (12):</b> | Adenoid hypertrophy in different age<br>group.....                               | 54              |
| <b>Figure (13):</b> | The clinical presentation among the<br>studied sample. ....                      | 55              |
| <b>Figure (14):</b> | Different clinical presentations in each<br>age group .....                      | 56              |
| <b>Figure (15):</b> | Antibiotic usage in different age group.....                                     | 56              |
| <b>Figure (16):</b> | Ear operations in different age groups .....                                     | 57              |
| <b>Figure (17):</b> | Anemic patients among studied sample .....                                       | 58              |
| <b>Figure (18):</b> | Different organisms obtained from<br>culture and sensitivity in our cohort. .... | 58              |

## Introduction

The predominant antibody deficiency syndromes include a heterogeneous group of disorders in which the fundamental defect is inability of B cells to produce an effective antibody response to pathogen (*Gatti & Hu, 2008*).

Patients with predominant antibody deficiency represent >50% of cases of primary immunodeficiency (*Latiff & Kerr, 2007*). Patients with predominant antibody deficiencies usually represent with repeated bronchopneumonia, upper respiratory tract infections, gastrointestinal infections and recurrent otitis media (*De Silva et al., 2007*).

Serum IgA level is used as a screening tool for predominant antibody deficiencies (*Oliveirad & Fleisher, 2010*).

Otitis media is the second most common infectious disease of childhood, after upper respiratory infection (*Yel, 2010*).

Young children in daycare very often get frequent upper respiratory tract infections and ear infection. Usually, parents and even pediatricians don't pay attention to long standing history of recurrent otitis media despite the possibility that it may be an alarm for predominant antibody diseases (*Sazgar et al., 2008*).

In the absence of early diagnosis and appropriate management, primary antibody deficiency can lead to serious morbidity and early mortality (*Wood et al., 2007*).

## **Aim of the work**

The aim of the present study is assessment of serum IgA level in pediatric patients with recurrent otitis media.

## **Introduction to the immune system**

The immune response is divided into two arms, the innate and adaptive, based on the speed and specificity of the reaction. The former is immediate and antigen independent while the latter develops over days to weeks, is antigen targeted and characterized by the development of immune memory (*Naik, 2003*).

The term innate immunity is sometimes used to include physical, chemical, and microbiological barriers, but more usually encompass the elements of the immune system (neutrophils, monocytes, macrophages, complement, cytokines and acute phase proteins), which provide immediate host defense (*Parkin & Cohen, 2001*).

Adaptive immunity is the hallmark of the immune system. The cells of the adaptive immune system include B cells and T cells which are the major types of lymphocytes and are derived from hematopoietic stem cells in the bone marrow (*Janeway et al., 2005*).

B-lymphocytes develop in the bone marrow and spleen through a series of stages from pluripotent precursor cells to mature B cells. This process does not require B-cell contact with antigen (*Bonilla & Fried, 2009*).

Antibodies can occur in two physical forms, a soluble form that is secreted from the cell, and a membrane-bound form

---

that is attached to the surface of a B cell and is referred to the B cell receptor (BCR). The BCR facilitates the activation of these cells and their subsequent differentiation into either plasma cells, or memory B cells (*Borghesi & Milcarek, 2006*).

Plasma cells and memory B cells represent the end stages of B cell differentiation and maturation. They are responsible for the continuous production of specific antibodies and long-lasting immunological memory, respectively (*Burg et al., 2009*).

The binding of antigen to the BCR induces BCR clustering and signaling cascades that lead to the activation of a variety of genes associated with B-cell activation (*Tolar et al., 2008*).

After leaving the bone marrow, IgM positive B cells activated by antigen in blood enter a germinal center in lymphoid tissues. Here, the interaction of B and T cells contributes to the generation of IgG, IgA, and IgE positive plasma cells and memory B cells by initiation of class switch recombination (CSR) (figure 1) (*Maródi & Notarangelo, 2007*).

Somatic hypermutation of the variable region of Ig heavy and Ig light chains increases the affinity of the BCR for antigen (*Driessen & Burg, 2011*).




Figure (1): B cell development & differentiation (*Driessen & Burg, 2011*).

## Immunoglobulin:

**Immunoglobulin** is a large Y-shaped protein produced by B-cells that is used by the immune system to identify and neutralize foreign objects such as bacteria and viruses. The antibody recognizes a unique part of the foreign target, called an antigen (*Janeway et al., 2005*).

All immunoglobulins have a four-chain structure as their basic unit. They are composed of two identical heavy and two identical light chains-kappas ( $\kappa$ ) or lambdas ( $\lambda$ ) which are common to all five immunoglobulins. The heavy and light chains are bound together by disulfide bonds and by non-covalent interactions (*Bonilla et al., 2012*).

Immunoglobulins can be divided into five different classes, based on differences in the amino acid sequences in the constant region of the heavy chains; gamma ( $\gamma$ ) in IgG, alpha ( $\alpha$ ) in IgA, mu ( $\mu$ ) in IgM, delta ( $\delta$ ) in IgD and epsilon ( $\epsilon$ ) in IgE (*Mayer, 2011*).

The heavy and light chains each have highly variable regions; which give the immunoglobulin specificity, and constant regions; in which there is virtual complete correspondence in amino acid sequence in all antibodies of a given isotype (eg. IgA, IgG, etc.) or isotype subclass (eg. IgG1, IgG2, etc.) (*Dalves & Roitt, 2000*). Hinge region is the region at which the arm of the antibody molecule forms a Y. It is called the hinge region because there is some flexibility in the molecule at this point. They can be broken into a constant Fc fragment and two highly variable Fab fragments (*Mayer, 2011*).

### **Immunoglobulin gene arrangement:**

The immunoglobulin heavy chain and light-chain genes occur on chromosomes 14, 2 and 22, respectively, in humans. In the embryonic germ line state the heavy-chain gene occur as separate segments for variable (V), diversity (D), joining (J) and constant (C) regions (*Albert & Inman, 2000*). During early differentiation of B cells, there is rearrangement of heavy-chain genes so that one of the V heavy-chain segments combines with one of the D segments already combined with one of the J segments. They thus form a transcriptional active gene for the heavy chain (*Hoffbrand et al., 2001*).

### **Immunoglobulin classes:**

#### **(1) Immunoglobulin G (IgG):**

IgG is composed of four peptide chains (two heavy chains  $\gamma$  and two light chains) (*Mayer, 2011*). It provides the majority of antibody-based immunity against invading pathogens (*Pier*

---